GeoVax Labs, Inc. New
GOVXGeoVax Labs, Inc. is a biotechnology company focused on developing innovative vaccines and immunotherapies for infectious diseases and cancers. The company leverages its proprietary MVA-VLP (Modified Vaccinia Ankara-Virus-Like Particle) platform to create candidates aimed at HIV, Ebola, Zika, and COVID-19, among others. GeoVax aims to advance its vaccine candidates through clinical trials to address unmet medical needs globally.
Company News
Following the WHO's declaration of a Public Health Emergency for the Bundibugyo virus Ebola outbreak on May 17, 2026, biodefense diagnostics companies are experiencing significant capital inflows. Co-Diagnostics is positioned as a strategic play due to its decentralized manufacturing network through joint ventures in India (CoSara) and Saudi Arab...
The WHO Africa regional director Mohamed Yakub Janabi warned against underestimating the Ebola outbreak in the Democratic Republic of Congo, which has reported 670 suspected cases and 61 confirmed infections. The Bundibugyo strain has no approved vaccine and has already spread to Uganda. Containment efforts are hampered by population movement, mi...
GeoVax Labs (GOVX) shares surged 16.42% to $2.34 as the company highlighted its MVA vaccine platform's potential to address emerging Ebola and hemorrhagic fever threats, following a WHO emergency declaration. The company announced a $3 million private placement and plans Phase 3 testing of its mpox and smallpox vaccine candidate in Q4 2026. Despi...
Several biotech companies are advancing cancer research with promising clinical milestones, focusing on innovative immunotherapies and targeted treatments amid rising cancer incidence and potential research funding challenges.
